References

Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. ImmunoTargets and therapy. 2023:25-45.

Peragallo JH. Pediatric myasthenia gravis. In Seminars in Pediatric Neurology 2017 May 1 (Vol. 24, No. 2, pp. 116-121). WB Saunders.

Bricoune O, Hamner B, Gieron-Korthals M. Challenges in Diagnosing and Treating Myasthenia Gravis in Infants and Children with Presentation of Cases. Advances in Pediatrics. 2023 Aug 1;70(1):81-90..

Gonçalves CS, Marques MIN, Antunes S, Serrano A, Serrano AM. Transient neonatal myasthenia gravis: a case report. Cureus. 2021;13(12).

Hassoun M, El Turjuman U, Chokr I, Fakhoury H. Myasthenia gravis in the neonate. Neoreviews. 2010;11(4):e200-e5.

Abicht A, Dusl M, Gallenmüller C, Guergueltcheva V, Schara U, Della Marina A, et al. Congenital myasthenic syndromes: Achievements and limitations of phenotype‐guided gene‐after‐gene sequencing in diagnostic practice: A study of 680 patients. Human mutation. 2012;33(10):1474-84.

Engel AG, Shen X-M, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. The Lancet Neurology. 2015;14(4):420-34.

Bird SJ, Shefner JM, Goddeau RP. Overview of the treatment of myasthenia gravis. Uptodate Topic. 2020;5157.

O'Connell K, Ramdas S, Palace J. Management of juvenile myasthenia gravis. Frontiers in Neurology. 2020 Jul 24;11:558150.1-12

Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune diseases. 2011 Oct;7:1-7

Cortés-Vicente E, Álvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020 Mar 17;94(11):e1171-80.

Evoli A, Iorio R. Controversies in ocular myasthenia gravis. Frontiers in neurology. 2020 Nov 30;11:605902.

Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. The Lancet Neurology. 2022 Feb 1;21(2):163-75.

Guptill JT, Sanders DB, Evoli A. Anti‐MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle & nerve. 2011 Jul;44(1):36-40.

Synmon B, Rawat S, Kynta R, Hussain M, Sharma SR, Lyngdoh BS, et al. Clinical spectrum of myasthenia gravis: An institute experience over 8 years from North East India. Journal of Family Medicine and Primary Care. 2022 Nov 1;11(11):7158-62.

Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. Journal of medicine and life. 2021 Jan;14(1):7.

T17. Yavuz P, Demir OO, Ozsurekci Y, Ozen S, Anlar B, Haliloglu G. New-onset ocular myasthenia after multisystem inflammatory syndrome in children. The Journal of Pediatrics. 2022 Jun 1;245:213-6.

Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Annals of the New York Academy of Sciences. 2003 Sep;998(1):413-23.

Heckmann JM, Europa TA, Soni AJ, Nel M. The epidemiology and phenotypes of ocular manifestations in childhood and juvenile myasthenia gravis: A review. Frontiers in neurology. 2022 Feb 23;13:834212.

Mansukhani SA, Bothun ED, Diehl NN, Mohney BG. Incidence and ocular features of pediatric myasthenias. American journal of ophthalmology. 2019 Apr 1;200:242-9.

Vecchio D, Ramdas S, Munot P, Pitt M, Beeson D, Knight R, et al. Paediatric myasthenia gravis: prognostic factors for drug free remission. Neuromuscular Disorders. 2020 Feb 1;30(2):120-7.

Barraud C, Desguerre I, Barnerias C, Gitiaux C, Boulay C, Chabrol B. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle & Nerve. 2018 Apr;57(4):603-9.

Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurological Sciences. 2013 Jun;34:911-7.

Wang W, Chen YP, Wang ZK, Wei DN, Yin L. A cohort study on myasthenia gravis patients in China. Neurological Sciences. 2013 Oct;34:1759-64.

Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. Journal of the neurological sciences. 2011 Jun 15;305(1-2):97-102.

Nafissi S, Okhovat AA, Sinaei F, Ansari B, Ayramloo H, Basiri K, et al. Iranian consensus recommendations for treatment of myasthenia gravis. Archives of Iranian Medicine. 2022 Jan 1;25(1):37-49.

Popperud TH, Boldingh MI, Rasmussen M, Kerty E. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. European Journal of Paediatric Neurology. 2017 Sep 1;21(5):707-14.

Lin Y, Kuang Q, Li H, Liang B, Lu J, Jiang Q, et al. Outcome and clinical features in juvenile myasthenia gravis: A systematic review and meta-analysis. Frontiers in Neurology. 2023 Mar 8;14:1119294.

Dragin N, Bismuth J, Cizeron-Clairac G, Biferi MG, Berthault C, Serraf A, et al. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. The Journal of clinical investigation. 2016 Apr 1;126(4):1525-37.

Gilhus NE, Tzartos S, Evoli A, Palace J,. BurnsTM & Verschuuren JJGM. Myasthenia Gravis. Nature Reviews Disease Primers. 2019 May 2 ;5:30

Levinson AI, Song D, Gaulton G, Zheng Y. The intrathymic pathogenesis of myasthenia gravis. Journal of Immunology Research. 2004 Sep 1;11(3-4):215-20.

Alahgholi-Hajibehzad M, Kasapoglu P, Jafari R, Rezaei N. The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics. Expert review of clinical immunology. 2015 Jul 3;11(7):859-70.

Leite MI, Jones M, Ströbel P, Marx A, Gold R, Niks E, et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. The American journal of pathology. 2007 Sep 1;171(3):893-905.

Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. The Lancet Neurology. 2022 Feb 1;21(2):163-75.

Rodríguez Cruz PM, Cossins J, Beeson D, Vincent A. The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis. Frontiers in molecular neuroscience. 2020 Dec 3;13:610964.

Borges LS, Richman DP. Muscle-specific kinase myasthenia gravis. Frontiers in Immunology. 2020 May 8;11: 707.511509.

Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research. 2016;5:1513

Huda R. New approaches to targeting B cells for myasthenia gravis therapy. Frontiers in immunology. 2020 Feb 21;11: 240. 510568.

Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort. Pediatric Neurology. 2018 Oct 1;87:36-

Kessi M, Tang Y, Chen B, Wang G, Zhang C, He F,et al. Pediatric ocular myasthenia gravis: single center experience. Pediatric Neurology. 2024 Jan 12.

Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. Journal of Neuro-Ophthalmology. 2011 Sep 1;31(3):239-40

Yamamoto D, Imai T, Tsuda E, Hozuki T, Yamauchi R, Hisahara S, et al. Effect of local cooling on excitation-contraction coupling in myasthenic muscle: another mechanism of ice-pack test in myasthenia gravis. Clinical Neurophysiology. 2017 Nov 1;128(11):2309-17.

Wong SH. Clinical signs in neuro-ophthalmology: Eye signs in myasthenia gravis. Annals of Indian Academy of Neurology. 2022 Oct 1;25(Suppl 2):S91-3.

Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009 Nov 1;116(11):2236-43.

Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. American journal of ophthalmology. 2010 Oct 1;150(4):453-9.

Europa TA, Nel M, Heckmann JM. Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle & Nerve. 2018 Oct;58(4):542-9.

Cleary M, Williams GJ, Metcalfe RA. The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus. 2008 Jan 1;16(1):11-8.

Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, et al. Myasthenia gravis with antibodies to MuSK: an update. Annals of the New York Academy of Sciences. 2018 Jan;1412(1):82-9.

Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscular Disorders. 2013 Nov 1;23(11):874-82.

Gui M, Luo X, Lin J, Li Y, Zhang M, Zhang X, et al. Long-term outcome of 424 childhood-onset myasthenia gravis patients. Journal of Neurology. 2015 Apr;262:823-30.

Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE, et al. The autoimmune spectrum of myasthenia gravis: a Swedish population‐based study. Journal of internal medicine. 2015 May;277(5):594-604.

Popperud TH, Gul KA, Brunborg C, Olaussen RW, Abrahamsen TG, Osnes LT, et al. Thymectomy in juvenile myasthenia gravis is safe regarding long term immunological effects. Frontiers in Neurology. 2021 Feb 25;12:596859.

VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics. 2013 Oct 1;132(4):e939-44.

Wong V, Hawkings BR, Yu YL. Myasthenia gravis in Hong Kong Chinese: 2. Paediatric disease. Acta neurologica scandinavica. 1992 Jul;86(1):68-72.

Heckmann JM, Hansen P, Van Toorn R, Lubbe E, Janse van Rensburg E, Wilmshurst J. The characteristics of juvenile myasthenia gravis among South Africans. South African Medical Journal. 2012 Jun 1;102(6):532-6.

Huang X, Li Y, Feng H, Chen P, Liu W. Clinical characteristics of juvenile myasthenia gravis in Southern China. Frontiers in neurology. 2018 Feb 27;9:77.

Cruz PR, Huda S, López-Ruiz P, Vincent A. Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Experimental neurology. 2015 Aug 1;270:66-71.

Yan C, Li W, Song J, Feng X, Xi J, Lu J, et al. Cell-based versus enzyme-linked immunosorbent assay for the detection of acetylcholine receptor antibodies in Chinese juvenile myasthenia gravis. Pediatric Neurology. 2019 Sep 1;98:74-9.

Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L, et al. Clinical findings in MuSK‐antibody positive myasthenia gravis: a US experience. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2010 Mar;41(3):370-4.

Huda S, Waters P, Woodhall M, Leite MI, Jacobson L, De Rosa A, et al. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurology: Neuroimmunology & Neuroinflammation. 2017 Jun 5;4(4):e357.

Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019 Jul 2;8(7):671.

Kostera-Pruszczyk A, Kwiecinski H. Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. Journal of neurology. 2009 Oct;256:1780-1.

Finlayson S, Beeson D, Palace J. Congenital myasthenic syndromes: an update. Practical neurology. 2013 Apr 1;13(2):80-91.

Finsterer J. Congenital myasthenic syndromes. Orphanet journal of rare diseases. 2019 Dec;14:1-22.

Pitt MC. Use of stimulated electromyography in the analysis of the neuromuscular junction in children. Muscle & Nerve. 2017 Nov;56(5):841-7.

Pitt MC, Mchugh JC, Deeb J, Smith RA. Assessing neuromuscular junction stability from stimulated EMG in children. Clinical Neurophysiology. 2017 Feb 1;128(2):290-6.

Hayashi A, Shiono H, Ohta M, Ohta K, Okumura M, Sawa Y. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis. Journal of neuroimmunology. 2007 Sep 1;189(1-2):163-8.

Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: an update. Journal of Clinical Medicine. 2021 Apr 6;10(7):1537.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. KInternational consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016 Jul 26;87(4):419-25.

Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. (2014) 13:CD006986 10.1002/14651858.CD006986.pub3

Nicolle MW. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum: Lifelong Learning in Neurology. 2016 Dec 1;22(6):1978-2005.

Liu GT,Volpe NJ,Galetta SL.Eyelid and facial nerve disorders. In: Neuro-Oohtalmology,LiuGT, Volpe NJ, Galetta SL (EDS),WB Saunders, Philadelphia 2001.p:496.

Munot P, Robb SA, Niks EH, Palace J, EWSC workshop study group . 242nd ENMC international diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord. (2020) 30:254–64.

Liew WK, Powell CA, Sloan SR, Shamberger RC, Weldon CB, Darras BT, et al. . Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. (2014) 71:575–80.

Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. (2009) 39:423–31.

Gold R, Hohlfeld R, Toyka KV. Progress in the treatment of myasthenia gravis. Therapeutic advances in neurological disorders. 2008 Sep;1(2):99-114.

Alami Z, Agier MS, Ahid S, Vial T, Dautriche A, Lagarce L, et al. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapies. 2018 May 1;73(3):199-207.

Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR‐antibody‐positive myasthenia gravis: outcomes in 102 patients. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2010 May;41(5):593-8.

Liu C, Gui M, Cao Y, Lin J, Li Y, Ji S, et al. Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatric Neurology. 2017 Dec 1;77:42-7.

Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. Journal of neuroimmunology. 2008 Mar 1;195(1-2):108-15.

Ponseti JM, Gamez J, Azem J, López‐Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Annals of the New York Academy of Sciences. 2008 Jun;1132(1):254-63.

Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. Journal of Clinical Medicine. 2022 Mar 14;11(6):1597.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016 Jul 5;87(1):57-64.

Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, Chac-Lezama G, López-Hernández JC, et al. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. Journal of Neurology. 2020 Mar;267:674-8.

Stathopoulos P, Dalakas MC. Evolution of anti-B cell therapeutics in autoimmune neurological diseases. Neurotherapeutics. 2022 Apr 1;19(3):691-710.

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Frontiers in immunology. 2019 Sep 6;10:1990.

Molimard A, Gitiaux C, Barnerias C, Audic F, Isapof A, Walther –Lauvier U, et al. Rituximab therapy in the treatment of juvenile Myasthenia gravis: the French experience. Neurology. 2022;98(23)

Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor KC. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Frontiers in immunology 2020;11:776.

Alipour-Faz A, Shojaei M, Peyvandi H, Ramzi D, Oroei M, Ghadiri F, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurologica Belgica. 2017 Mar;117:245-9.

Liew WK, Powell CA, Sloan SR, Shamberger RC, Weldon CB, Darras BT, et al.. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurology. 2014; 71:575–80.

Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011; 76:2017–23.

Seyhanli A, Yavuz B, Selimoglu I, Sengun IS, Aslan AT, Ozsan GH, et al. Therapeutic plasma exchange in neurological diseases: Eleven years experience at a tertiary care center in Turkey. Therapeutic Apheresis and Dialysis. 2022 Apr;26(2):465-70.

Aljaafari D, Ishaque N. Thymectomy in myasthenia gravis: A narrative review. Saudi Journal of Medicine & Medical Sciences. 2022 May 1;10(2):97-104.

Chang CC, Lin TM, Chang YS, Chen WS, Sheu JJ, Chen YH, et al.. Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. Rheumatology. (2019) 58:135–43.

Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). The Lancet Neurology. 2020 Dec 1;19(12):970-1.

Lin MW, Chang YL, Huang PM, Lee YC. Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors. European journal of cardio-thoracic surgery. 2010 Jan 1;37(1):7-12.

Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Noninvasive ventilation in myasthenic crisis. Archives of neurology. 2008 Jan 1;65(1):54-8.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016 Jul 26;87(4):419-25.

Albazli K, Kaminski HJ, Howard Jr JF. Complement inhibitor therapy for myasthenia gravis. Frontiers in Immunology. 2020 Jun 3;11:917.

Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Review of Clinical Immunology. 2022 Jul 3;18(7):691-701.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & nerve. 2019 Jul;60(1):14-24.

Howard Jr JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody–positive generalized myasthenia gravis. Expert Opinion on Investigational Drugs. 2021 May 4;30(5):483-93.

Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, et al. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences. 2021 Nov 15;430:118074.

Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 2021 Jul 1;20(7):526-36.